Table 1.
Patient characteristics.
| Characteristic | All, n = 1047 | CV Event, n = 97 | No CV Event, n = 950 | p |
|---|---|---|---|---|
| Age, yrs, mean (range) | 63.7 (21–91) | 64.6 (48–88) | 63.6 (21–91) | 0.325 |
| Male, % (n) | 90.9 (952) | 96.9 (94) | 90.3 (858) | 0.031 |
| White, % (n) | 78.3 (819) | 81.44 (79) | 78.0 (740) | 0.430 |
| Education, yrs (SD) | 12.7 (2.4) | 11.9 (2.1) | 12.8 (2.5) | 0.001 |
| Body mass index, kg/m2* (SD) | 28.3 (5.8) | 27.9 (6.2) | 28.3 (5.7) | 0.551 |
| Alcohol abuse, % (n) | 8.69 (91) | 10.31 (10) | 8.53 (81) | 0.553 |
| Hypertension, % (n) | 71.35 (747) | 82.5 (80) | 70.21 (667) | 0.011 |
| Hyperlipidemia, % (n) | 52.1 (545) | 63.9 (62) | 50.8 (483) | 0.014 |
| Diabetes, % (n) | 25.2 (264) | 30.9 (30) | 24.6 (234) | 0.174 |
| Urban, % (n) | 71.4 (748) | 77.3 (75) | 70.8 (673) | 0.179 |
| Modified Charlson-Deyo index (SD) | 1.7 (2.0) | 2.7 (2.5) | 1.6 (1.9) | < 0.0001 |
| Prior cardiovascular event, % (n) | ||||
| MI | 15.7 (164) | 35.1 (34) | 13.7 (130) | < 0.001 |
| HF | 13.3 (139) | 20.6 (20) | 12.5 (119) | 0.025 |
| PVD | 14.7 (154) | 25.77 (25) | 13.6 (129) | 0.001 |
| PCI | 2.6 (27) | 5.2 (5) | 2.3 (22) | 0.096 |
| CABG | 1.0 (10) | 2.0 (2) | 0.84 (8) | 0.235 |
| Stroke | 4.58 (48) | 11.34 (11) | 3.89 (37) | 0.003 |
| RA duration, yrs (SD) | 14.5 (12.2) | 15.1 (12) | 14.4 (12.2) | 0.614 |
| Radiological changes, % (n) | 71.2 (730) | 71.3 (67) | 71.2 (663) | 0.990 |
| Mean DAS28 (SD) | 3.7 (1.18) | 3.9 (1.2) | 3.7 (1.2) | 0.225 |
| Rheumatoid factor-positive, % (n) | 89.1 (930) | 94.9 (92) | 88.5 (838) | 0.056 |
| ACPA-positive, % (n) | 81.4 (745) | 84.7 (72) | 81.1 (673) | 0.414 |
| Mean CRP, mg/dl (SD) | 13.1 (20) | 14.9 (20) | 12.9 (20) | 0.354 |
| Rheumatoid nodules, % (n) | 59.1 (574) | 62.0 (57) | 58.8 (517) | 0.560 |
| Observation time (days), mean (SD) | 1549.6 (483.1) | 1738.3 (443.0) | 1530.3 (483.1) | < 0.0001 |
| Smoking status, % (n) | ||||
| Never | 20.3 (212) | 15.5 (15) | 20.8 (197) | 0.290 |
| Former | 52.4 (548) | 51.55 (50) | 52.5 (498) | |
| Current | 27.3 (286) | 33.0 (32) | 26.8 (254) | |
| Methotrexate use, % (n) | 51.2 (536) | 49.5 (48) | 51.4 (488) | 0.724 |
| Glucocorticoid ever-user, % (n) | 63.9 (669) | 69.1 (67) | 63.4 (602) | 0.265 |
| MTHFR A1298C† (rs1801131), % (n) | ||||
| AA | 50.1 (523) | 43.1 (47) | 50.2 (476) | 0.689 |
| AC | 39.1 (409) | 38.1 (37) | 39.24 (372) | |
| CC | 10.8 (113) | 13.4 (13) | 10.6 (100) | |
| MTHFR C667T† (rs1801133), % (n) | ||||
| CC | 50.1 (524) | 54.6 (53) | 49.7 (471) | 0.023 |
| CT | 39.8 (416) | 43.3 (42) | 39.5 (374) | |
| TT | 10.1 (105) | 2.1 (2) | 10.86 (103) | |
| HLA-DRB-1 SE*, % (n) | ||||
| 2 copies | 21.0 (218) | 18.75 (18) | 21.2 (200) | 0.724 |
| 1 copy | 51.0 (530) | 50.0 (48) | 51.1 (482) | |
| 0 copies | 28.1 (292) | 31.25 (30) | 27.8 (262) |
†
Polymorphisms are listed in order of major allele homozygous, heterozygous, minor allele homozygous.
*
Missing data for HLA-DRB-1 SE = 26.4% (n = 276).
MI: myocardial infarction; CV: cardiovascular; DAS28: 4-variable Disease Activity Score using 28-joint count and erythrocyte sedimentation rate; ACPA: anticitrullinated protein antibody; MTHFR: methylenetetrahydrofolate reductase; DRB-1: HLA subtype; HF: heart failure; PVD: peripheral vascular disease; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; RA: rheumatoid arthritis; CRP: C-reactive protein.